Melanoma Biobank

核心A -黑色素瘤生物样本库 人类癌细胞的繁殖已经成为癌症生物学的重要组成部分， 发现黑色素瘤中的BRAF突变。从历史上看，癌细胞系已被证明是一种强大的 筛选新的治疗化合物和分离敏感性的分子决定因素的系统 到抗癌药物。核心A-黑色素瘤生物库（MBB）的主要职责是建立一个关键的 一组来自接受选择性Braf抑制剂或其他药物治疗的患者的黑素瘤细胞系 新型药剂核心A的重要衍生物，沿着注释标本，将提供给其他人 用于可能出现的靶候选物的分子验证和功能验证 从不同的屏幕。核心A的具体目的是（1）提供黑色素瘤的中心来源 在开始选择性Braf抑制剂（SBIs）之前和在复发期间获得的细胞， 治疗，（2）提供细胞上的突变、拷贝数、表达和途径激活谱 线和（3）提供选择性BRAF抑制剂和其他靶向治疗的敏感性数据， 比较各种靶向药物的药物反应，以及（4）维护临床数据库， 来自靶向治疗试验患者的组织库。这最后一个目标将利用现有的 资金，并将提供一个关键的一块相关的难题，在整个翻译工作。由 在资助期结束时，POI内所有项目和核心的成功整合将产生 前所未有的一套组织标本和活细胞装饰着细致的临床注释和深入的 分子分析

Core A - Melanoma Biobank The propagation of human cancer cells has been a vital part of cancer biology including the seminal discovery of BRAF mutations in melanoma. Historically, cancer lines have proven to be a powerful system for screening novel therapeutic compounds and for isolating molecular determinants of sensitivity to anti-cancer drugs. The main charge of Core A- the Melanoma Biobank (MBB)- is to establish a critical set of melanoma cell lines from patients who undergo treatment with selective Braf inhibitors or other novel agents. Vital derivatives from Core A, along with annotated specimens, will be available to the rest of the P01 for molecular verification and functional validation of target candidates which may emerge from the various screens. The Specific Aims of Core A are (1) to provide a central source of melanoma cells obtained prior to initiation of selective Braf inhibitors (SBIs) and during relapse while undergoing treatment, (2) to provide mutational, copy number, expression and pathway actiyation profiles on cell lines and (3) to provide sensitivity data for selective BRAF inhibitors and other targeted therapies and to compare drug responses across various targeted agents and (4) to maintain a clinical database and tissue repository derived from patients on targeted therapy trials. This last Aim will leverage extant funding and will provide a critical piece of the correlative puzzle in the overall translational effort. By the end of the funded period, successful integration of all Projects and Cores within the POI will yield an unprecedented set of tissue specimens and vital cells adorned with meticulous clinical annotation and in-depth molecular profiling.